Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GNR-127

Biologic

GNR-127 is one of 30 biologic programs targeting Allergic Rhinitis. It is currently in development.

1

Indications

1

Total Trials

1

Active Trials

29

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Kenalog

BBassett Healthcare

Comparator: Statins

Bepreve

BBausch Health Americas, Inc.

Standard Adjuvant ET

Flonase

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Asmanex

Administration of Comparator

EEurofarma Laboratorios S.A.

Veramyst

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.

Active, not recruiting·AAO GENERIUM·Phase 1/2·NCT07155499·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GNR-127. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNR-127 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNR-127. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AO GENERIUM company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: AAO GENERIUM

Related News